{"page_content": "Notes\nNote 7 \u2013 Income tax (continued)\nDKK thousand     2021  2020\nTax on equity\nWarrants - shareprice development\n    5\n,588\n 2,325\nChange in tax assets (not r\necognized)\n    -5\n,588\n -2,325\nT\notal income tax expense (income)\n    0\n 0\n     \nDKK thousand\n    2021\n \n2020\nSpecification of unrecognized deferred tax assets:\n   \nT\nax losses carried forward (available indefinitely)\n    2,231,\n010\n 1,269\n,107\nResearch and development expenses\n    842,\n775\n 732,389\nLicenses, rights and pa\ntents\n    41,512\n 36\n,260\nNon-current assets\n    88\n,676\n 66\n,179\nLiabilities\n    73\n,444\n 131,1\n47\nOther\n    30\n,822\n 51,\n413\nTotal temporary differences\n    3\n,308,239\n 2,286\n,495\n     \nPlease r\nefer to note 11 in the consolidated financial statements for additional information regarding \nincome tax.Note 6 - Other operating income and expenses\nDKK thousand     2021  2020\nGovernment grants\n    759\n 645\nContributed IP rights to Z\nealand Pharma SPV 3 K/S\n   0\n 35\n,496\nOther\n    0\n 855\nT\notal other operating income\n    759\n 36\n,996\nOther\n    -2,161\n 0\nT\notal other operating expenses\n    -2,161\n 0\nPlease r\nefer to note 8 in the consolidated financial statements for additional information regarding other \noperating income and expenses\nNote 7 \u2013 Income tax\nDKK thousand     2021  2020\nNet result for the year before tax\n    -1,\n011,529\n -832,342\nCorpora\nte tax rate in Denmark\n    22.\n0%\n 22.\n0%\n     \nExpected tax benefit/(expenses)\n    -222,536\n -183\n,115\nAdjustment for non-deductible expenses\n    5\n,469\n 1,\n873\nAdjustment for non-taxable income\n    -8\n,084\n -7\n,181\nAdjustment for warrants\n    6\n,501\n -72\nAdjustment f\nor R&D extra deduction\n    -1\n4,379\n -8\n,811\nAdjustment to prior years\n    -5\n,143\n 313\nChange in tax assets (not r\necognized)\n    231,2\n47\n 191,\n450\nTotal income tax expense/benefit\n    -6\n,925\n -5\n,543104\nZealand Pharma  \u221e  Annual Report 2021Par Fin \u2013 Note 7-8", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 103, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}